AGT, has a broad, robust lentiviral delivery platform evolved over ten years of advanced development. AGT has an extensive and growing patent portfolio surrounding its lentiviral platform innovations that accelerate the development of a wide variety of drug candidates. This platform allows AGT to pursue exciting clinical “cures” in large and orphan indications and complex diseases. AGT’s proprietary platform technologies provide reusable components that allow AGT and its internationally recognized collaborators to create new drugs in a fraction of the time of traditional drug development processes and other drug companies. AGT will begin clinical trials this year for an HIV functional cure based on a successful pre-IND meeting with FDA in October of 2016.